Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Safety of Telitacicept in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07597733 is registered in ClinicalTrials.gov with Sichuan Academy of Medical Sciences as lead sponsor.

NCT NCT07597733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07597733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Safety of Telitacicept in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Lead sponsor
Sichuan Academy of Medical Sciences
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 26, 2025
Completion date
August 31, 2027
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic inflammatory demyelinating polyneuropathy